The NOVA team has been involved in ion channel research since the 1980’s. They have a long history of providing data for regulatory guidelines. For instance, we conducted the hERG screening for the original ILSI/HESI safety study which became the groundwork for the current S7B guidelines, and members of our team have been contracted by the FDA to provide ion channel screening in support of the new CiPA safety assessment guidelines. NOVA has worked with 100’s of companies along with multiple government agencies to help de-risk compounds.
The NOVA Difference
GLP hERG (IKr)
Other GLP ion channels:
Cardiac Action Potential
Cardiac action potentials allow an integrated look at the effects of a drug on ion channels important in cardiac conduction and repolarization.
The Comprehensive in vitro Proarrhythmic Assay (CiPA) is a series of assays designed to predict arrhythmias and not simply QT prolongation.
Nova staff have provided the manual ion channel data for the FDA which has been used to parameterize the in silico action potential model and provide a benchmark for the ILSI/HESI automated patch clamp study.
With our experienced staff, we can fulfill all of the CiPA recommendations.
Our protein binding assays allow for the characterization of serum proteins onion channel block. Only the free (unbound) form of the drug can interact with ion channels. If the protein binding of your drug is not known or if there is a species-dependent difference in protein binding, this assay can provide valuable insight.
Using the manual patch clamp technique, the potency of your drug can be examined in the presence and absence of human serum albumin. This will allow for a more relevant comparison with in vivo concentrations.
This assay can be performed on any of the following:
Biomolecular Interaction Analysis Services
Biochemistry & Molecular Biology Services
Nova Research Labs LLC. has not received any reviews.
Nova Research Labs LLC. has not received any endorsements.